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Abstract
Donor- specific alloantibodies (DSA) have been associated with rejection and shorter 
graft survival after orthotopic liver transplantation (OLT). We examined the role of 
DSA in nonanastomotic biliary strictures (NAS) after OLT. Patients receiving first OLT 
who developed NAS (n = 68) and a control group without NAS (n = 83), with pre- OLT 
and 12 months post- OLT serum samples, were included. DSA were specified using the 
Luminex single antigen test. Risk factors for NAS and graft survival were analyzed. The 
presence of preformed DSA was not significantly different between patients with NAS 
and controls (P = .89). After 12 months, 26.5% of NAS patients and 16.9% of controls 
had generated de novo DSA (P = .15). Neither de novo class I DSA nor de novo class II 
DSA were associated with NAS. De novo DSA generally developed after the diagnosis 
of NAS. Time- dependent regression analysis identified both NAS (aHR 8.05, CI 3.28 
– 19.77, P < .01) and de novo class II DSA (aHR 2.84, CI 1.38 – 5.82, P < .01) as inde-
pendent risk factors for graft loss. Preformed or de novo DSA were not associated 
with the development of NAS. However, NAS as well as de novo class II DSA were 
independent risk factors for graft loss after OLT.
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1  | INTRODUCTION
The presence of donor- specific alloantibodies (DSA) against human 
leukocyte antigen (HLA) has been associated with (hyper)acute rejec-
tion and shorter graft survival after organ transplantation in general.1,2 
Yet, after orthotopic liver transplantation (OLT), preformed DSA can 
be absorbed by the graft and hyperacute rejection as a result of DSA 
is rare.3-5 While ABO compatibility is required, the presence of DSA 
or a positive HLA crossmatch is not considered a contraindication to 
OLT.6 Despite the absence of hyperacute rejection, recent studies 
have shown that DSA may be a more relevant predictor of patient and 
graft outcome after OLT than previously assumed. In a large study co-
hort, preformed class II DSA were associated with both early graft loss 
and rejection.7 In addition, Kaneku et al recently found that de novo 
DSA, formed after OLT, were detected in 8% of the patients and were 
associated with a significantly impaired patient and graft survival.8 
Furthermore, it has been suggested that de novo DSA with a high 
mean fluorescence intensity (MFI) are associated with chronic rejec-
tion after OLT.9
Nonanastomotic biliary strictures (NAS) can be defined as intra- 
and extrahepatic lesions of the biliary tree more than 1 cm above the 
anastomosis, characterized by bile duct strictures and dilatations.10,11 
Reported incidences of treated NAS vary between 9% and 31%. 
NAS are considered a major cause of morbidity and reduced graft 
survival after OLT.12 Whereas the complete pathogenesis of NAS is 
still unclear, several risk factors such as ischemia- reperfusion injury,13 
grafts donated after cardiac death and damage from bile salt toxic-
ity have been identified.14,15 Besides these factors, a contribution of 
immune- mediated cholangiocyte injury has been proposed.16 This is 
supported by reports on an increased incidence of NAS in the cases 
of ABO incompatibility, underlying disease with assumed autoimmune 
etiology—such as primary sclerosing cholangitis (PSC) and autoim-
mune hepatitis—in patients with a genetic chemokine receptor five 
loss of function, and after cytomegalovirus viremia (CMV).17-20 The 
biliary epithelium has been shown to express HLA class I and class II 
molecules after OLT,21 and the presence of antibodies against these 
antigens may therefore possibly be a factor contributing to NAS de-
velopment. Indeed, earlier studies demonstrated that the presence of 
preformed DSA leading to a positive cytotoxic crossmatch was associ-
ated with bile duct complications in general and/or with preservation 
injury, which is an important risk factor for NAS development.10,22-25 
Therefore, the aim of this study was to evaluate the relationship be-
tween preformed and de novo DSA with the development of NAS and 
with graft survival after OLT.
2  | PATIENTS AND METHODS
Patients receiving ABO- compatible OLT in two Dutch transplanta-
tion centers between 2000 and 2014 who developed NAS (n = 68) 
and a control group of OLT patients without NAS matched for 
recipient age, recipient gender, etiology, and acute rejection, and 
transplanted in the same time period (n = 83), of whom pre- OLT 
and 12 months post- OLT serum samples were available, were se-
lected for this study. Duration of follow- up was at least 1 year 
for all patients. Presentation was with bacterial cholangitis, jaun-
dice and/or itching in around one- third of cases, all with choles-
tatic liver enzymes. In two- thirds of patients, no symptoms were 
present, while elevated serum alkaline phosphatase and gamma- 
glutamyltransferase, and bilirubin in some, prompted further in-
vestigation. In all NAS patients, the diagnosis was confirmed with 
direct cholangiography, that is, endoscopic retrograde cholangio-
graphy or percutaneous transhepatic cholangiography. In all cases 
diagnosed with NAS, biliary strictures more than 1 cm above the 
biliary anastomosis were present as determined by at least two en-
doscopists and conformed in a multidisciplinary radiology meeting. 
Moreover, a strict definition of NAS was used, which required that 
the biliary strictures should have been treated at least once by dila-
tation and/or stenting by ERCP or PTC, ensuring that the strictures 
were considered clinically significant. In this cohort, only a minority 
underwent MRI- MRCP first. In all of these cases, NAS was intrahe-
patic and most often diffuse. Some were only perihilar, a minority 
in addition had extrahepatic nonanastomotic biliary strictures. Only 
patients without vascular (eg, hepatic artery thrombosis) or other 
biliary complications were included. Hepatic artery thrombosis or 
stenosis and other complications were excluded by Doppler ultra-
sound or CT angiography in all cases.
Graft survival was determined as time of transplantation until 
graft loss (retransplantation or death) or in case of no event, until the 
end of the study (June 2014). Time to NAS was determined as time 
from transplantation until detection of NAS or in case of no event, 
until graft loss or the end of the study (June 2014). Demographic and 
clinical data of liver transplant recipients, like age, gender, etiology 
of liver disease and post- transplant complications, were derived from 
the electronic patient charts. Immunosuppression in both centers was 
similar, consisting of induction with basiliximab and methylpredniso-
lone, followed by tacrolimus, or—in some cases—cyclosporin micro-
emulsion, prednisolone for 6 months and in some cases addition of 
mycophenolate mofetil, azathioprine or—after 3 months—everolimus 
or sirolimus.
The study was approved by the Medical Ethics Committee 
(Protocol B14.014) and in accordance with the Declaration of Helsinki. 
All patients gave informed consent to donate pretransplantation and 
post- transplantation blood samples for research purposes, without 
given preference to any explicit clinical variables. Only patients with a 
minimum age of 18 years who gave informed consent and donated a 
blood sample were included in the study.
2.1 | Human leukocyte antigen typing and  
determination of anti- HLA class I and class II 
alloantibodies
Patient and donor DNA samples were genotyped using either the 
sequence- specific oligonucleotide probe (PCR/SSOP) technique 
for HLA- DR and HLA- DQ, or the reverse SSO method on a sus-
pension array platform using microspheres as a solid support to 
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immobilize oligonucleotide probes (for HLA- A and HLA- B: Lifecodes 
from Immucor Transplant Diagnostics Inc., Stamford, CT, USA). 
Serum samples from recipients were screened for the presence of 
anti- HLA alloantibodies using the Lifecodes Lifescreen Deluxe (LMX) 
kit, according to the manufacturer’s manual (Immucor Transplant 
Diagnostics Inc.). Samples that were positive for either HLA class I 
(HLA- A or HLA- B) or HLA class II (HLA- DQ or HLA- DR) antibodies 
were further analyzed with a Luminex single antigen assay, using 
LABscreen HLA class I and class II antigen beads (One Lambda, 
Canoga Park, CA, USA). Briefly, 4 μL of LABscreen beads and 20 μL of 
serum were mixed in a test well, protected from light. Serum samples 
were incubated for 30 minutes. at room temperature on a rotating 
platform (150 rpm), followed by repeated washings with 260 μL wash 
buffer (1X). Afterward, each sample was incubated for 30 minutes. 
with a goat anti- human PE- conjugated antibody (1:100 wash buffer) 
at room temperature, protected from light, and subsequently washed 
five times with wash buffer. Samples were measured using a Luminex 
100 reader (Luminex 100, Luminex Corporation, ‘s- Hertogenbosch, 
the Netherlands). LABscreen negative control serum (LS- NC, One 
Lambda) was used as a negative control. Antibodies detected with a 
MFI of >5000 were considered positive, as DSA levels above this cut-
off value are associated with clinically relevant outcomes after OLT.7,8
2.2 | Statistical analysis
Statistical analysis was performed using SPSS version 20.0 for win-
dows (SPSS Inc., Chicago, IL, USA). Continuous data were analyzed 
using Student t test or Mann- Whitney U test. Chi- square test was 
performed for categorized data. A risk factor analysis for NAS and for 
graft loss was performed using univariate and (for univariate factors 
with P < .10) multivariate Cox regression analyses for baseline fac-
tors with forward selection and backward exclusion. Both NAS and 
de novo class II DSA were considered risk factors for graft loss, and as 
these predictors occur in the course of time, instead of being baseline 
variables, these factors were taken into account as time- dependent 
covariates in a time- dependent Cox regression analysis. A P- value of 
<.05 was considered statistically significant.
3  | RESULTS
3.1 | Patients
In total, 68 patients with nonanastomotic biliary strictures (NAS) 
and 83 controls without NAS after first OLT were included in this 
study. Median age of all recipients at time of transplantation was 
55 (IQR 46- 61) years. In 31 patients (20.5%), OLT was performed 
with a graft from donation after circulatory death (DCD). Median 
time from OLT to diagnosis of NAS was 5.5 months (IQR 1.6- 12.8). 
Baseline characteristics of patients with and without NAS are ex-
pressed in Table 1. No significant differences were found between 
patients with and without NAS, including the incidence of acute cel-
lular rejection, with the exception of DCD- OLTs: As expected, NAS 
developed more frequently in recipients who received a DCD graft 
as compared to a liver after donation after brain death (DBD) dona-
tion (P < .01).
3.2 | Donor- specific antibodies and NAS
Preformed DSA were detected in 10.3% (n = 7) of the NAS patients 
and in 9.6% (n = 8) of the controls (Table 2). The presence of pre-
formed class I DSA or preformed class II DSA was not significantly 
different between patients with NAS and controls in chi- square test. 
Female patients were more likely to have generated DSA before 
transplantation (female 20.4% vs male 4.1%, P < .01). DSA did not 
develop more frequently in patients transplanted with a DCD graft 
(DBD 22.5% vs DCD 16.1%, P = .44). 1 year after OLT, 32 patients 
(21%) generated de novo DSA. In 29 of 32 patients (90.6%) who 
TABLE  1 Baseline characteristics. Data are presented as median 
(interquartile range) for continuous variables. Categorized data are 
presented as number (percentage)
NAS 
(n = 68)
Controls 
(n = 83) P- value
Donor age 47 (37 – 55) 47 (36 – 58) .980
Donor gender .364
Male 37 (54.4) 39 (47.0)
Female 31 (45.6) 44 (53.0)
Recipient age 55 (45 – 62) 54.0 (47 – 60) .928
Recipient gender .429
Male 46 (67.6) 51 (61.4)
Female 22 (32.4) 32 (38.6)
Etiology .854
Viral 7 (10.3) 11 (13.3)
ALD 13 (19.1) 13 (15.7)
PSC 13 (19.1) 17 (20.5)
HCC 14 (20.6) 21 (25.3)
Othera 21 (30.9) 21 (25.3)
CMV mismatch 
(D+/R−)
28 (47.5) 44 (53.7) .467
Episode of acute 
rejection
14 (20.6) 12 (14.5) .321
Donation after 
cardiac death
24 (35.3) 7 (8.4) .000
Donor BMI 24 (23 – 27) 24 (22 – 26) .573
Recipient BMI 25 (23 – 28) 25 (23 – 28) .731
DWIT (min) in 
DCD
20 (16 – 29) 17 (13 – 20) .645
CIT (min) 438 (382 – 558) 452 (369 – 546) .444
RWIT (min) 33 (26 – 42) 31 (24 – 34) .148
NAS, nonanastomotic biliary strictures; ALD, alcoholic liver disease; PSC, 
primary sclerosing cholangitis; HCC, hepatocellular carcinoma; CMV, cyto-
megalovirus; BMI, body mass index; DWIT, donor warm ischemia time; 
CIT, cold ischemia time; RWIT, recipient warm ischemia time. Significant 
values are printed bold.
aOther indications include: auto- immune hepatitis, nonalcoholic steato-
hepatitis and polycystic liver disease.
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generated de novo DSA, the newly developed antibodies were di-
rected against the HLA class II antigens of the donor, in most of the 
cases against HLA- DQ (69% DQ only, 14% DR only and 17% both 
DQ and DR). Overall, the development of DSA post- transplantation 
was not related to NAS development, as 26.5% of NAS patients and 
16.9% of the controls had de novo DSA 1 year after OLT (P = .15). 
Neither de novo class I DSA nor de novo class II DSA were signifi-
cantly more often present in patients with NAS, as compared to 
controls (Table 2). The incidence of alloantibodies directed at an-
tigens of the individual loci, that is, HLA- A, HLA- B, HLA- DQ and 
HLA- DR, was also not different between the two groups (data not 
shown). We further analyzed the cumulative MFI of DSA between 
patients with NAS and controls; however, no significant difference 
was found (13601 vs 10 925, P = .27).
Univariate and multivariate analyses of pre- OLT risk factors for de-
veloping NAS are shown in Table 3. As expected a DCD donor was a 
risk factor for NAS in both univariate and multivariate analyses, while 
a donor with a positive CMV IgG status was a risk factor in univariate 
analysis with only a trend in multivariate analysis. Preformed DSA over-
all and class I and II apart were not risk factors for NAS, and likewise, 
the other examined factors were not a risk for developing NAS (Table 3). 
Univariate and multivariate analyses for baseline risk factors were also 
examined after exclusion of DCD OLT: In DBD OLT, a trend existed for 
RWIT as a risk factor for NAS in both univariate and multivariate anal-
yses, and no significant risk factors for NAS were found here (Table 4). 
In the whole cohort and in DBD OLT, there was also no relationship be-
tween DSA against various HLA antigens and NAS with MFI of >1000 
(instead of >5000) as cutoff for the presence of DSA (Tables 3 and 4).
Longitudinal analysis in a subgroup of NAS patients (n = 20) 
showed that preexisting DSA against class I HLA usually disappeared 
within the first 6 months after transplantation. De novo class I DSA 
tended to develop early after OLT, but were usually already cleared 
TABLE  2 Prevalence of preformed and de novo DSA (mean 
fluorescence intensity [MFI]>5000) in patients with nonanastomotic 
biliary strictures (NAS) and controls
NAS (n = 68) Controls (n = 83) P- value
Preformed
Any DSA 7 (10.3) 8 (9.6) .893
Class I 4 (5.) 7 (8.4) .548
Class II 2 (2.9) 1 (1.2) .447
Class I and II 1 (1.5) 0 .268
De novo
Any DSA 18 (26.5) 14 (16.9) .151
Class I 3 (4.4) 0 .053
Class II 15 (22.1) 14 (16.9) .420
 Data are presented as n (%).
Univariate analysis Multivariate analysis
HR (95% CI) P- value HR (95% CI) P- value
Donor age 1.00 (0.98 – 1.02) .835
Donor gender male 
CMV IgG donor positive
0.93 (0.56 – 1.59) 
0.54 (0.32 – 0.92)
.826 
.023
1.61 (0.93 – 2.78) .088
CMV mismatch (D pos/R neg) 
CMV IgG recipient positive
0.73 (0.35 – 1.53) 
0.77 (0.42 – 1.43)
.409 
.403
Recipient age 
Recipient gender male
1.01 (0.99 – 1.04) 
1.21 (0.73 – 1.01)
.404 
.472
Gender mismatch 
BMI donor
0.89 (0.53 – 1.51) 
1.01 (0.93 – 1.09)
.669 
.854
OLT indication groupeda
OLT indication PSC
         (0.66 – 1.24) 
1.36 (0.61 – 2.13)
.540 
.690
Roux- en- Y anastomosis MELD 
score recipient
0.65 (0.34 – 1.27) 
1.01 (0.95 – 1.08)
.208 
.791
Donor type DCD 3.02 (1.82 – 4.76) .000 2.67 (1.47 – 4.87) .001
Preformed DSA Type I (>5000) 
Preformed DSA Type II (>5000)
1.01 (0.41– 2.51) 
0.62 (0.15 – 2.56)
.988 
.152
Preformed DSA Type I (>1000) 
Preformed DSA Type II (>1000)
1.22 (0.52 – 2.82) 
1.13 (0.36 – 3.62)
.650 
.832
CIT 
RWIT
1.00 (0.99 – 1.01) 
1.01 (0.99 – 1.03)
.507 
.221
HR, hazard ratio; CI, confidence intervals; OLT, orthotopic liver transplantation; CMV, cytomegalovirus; 
DBD, donation after brain death; DCD, donation after circulatory death; BMI, body mass index; NAS, 
nonanastomotic biliary strictures; DSA, donor- specific antibodies against human leukocyte antigen 
(HLA) (mean fluorescence intensity (MFI)>5000). Significant values are printed bold.
aViral, alcoholic, (PSC) primary sclerosing cholangitis, or other underlying liver disease.
TABLE  3 Univariate and multivariate 
analyses of risk factors for NAS (all 
patients)
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from the circulation at 12 months. Class II DSA were more likely to 
be persistent (data not shown). Importantly, in NAS patients, de novo 
DSA generally developed after the diagnosis of NAS (Figure 1, patients 
1,2,5,7,8,9,10,11,12,13,14,16,19).
3.3 | Donor- specific alloantibodies and graft survival
In total, 19 (12.6%) patients died and 15 (9.9%) patients required 
a retransplantation during follow- up. Univariate and multivariate 
analyses of possible baseline risk factors for graft survival revealed 
male sex and donor BMI as independent risk factors for graft loss. 
Time- dependent Cox regression analysis identified NAS (aHR = 8.05, 
95% CI 3.28 – 19.77, P < .01) and de novo class II DSA (aHR = 2.84, 
95% CI 1.38 – 5.82, P < .01) as independent risk factors for graft loss 
(Table 5). De novo DSA after OLT had a similar impact on graft sur-
vival in patients with NAS and in controls (P = .10).
In the NAS group, 15 retransplantations were carried out for NAS 
with recurrent bacterial cholangitis (n = 13), infection unrelated to 
NAS (n = 1) and chronic rejection (n = 1). In the NAS group 13 patients 
died; causes of death were recurrent cholangitis (n = 1), chronic re-
jection (n = 1), cholangitis from recurrent PSC (n = 1), pulmonary em-
bolism (n = 1), multi- organ failure (n = 1), malignancy (n = 2), infection 
unrelated to NAS (n = 2), unknown (n = 4). In the control group without 
NAS, no patient underwent retransplantation and six died; causes of 
death were infection (n = 2), malignancy (n = 2), and unknown (n = 2).
4  | DISCUSSION
The present study demonstrated that both NAS and DSA against 
HLA class II- generated post- transplantation have a significant impact 
on graft survival. Yet, neither preformed, nor de novo DSA directed 
against class I or class II HLA antigens are associated with an increased 
risk for NAS development. Preformed DSA often disappear after OLT, 
while de novo DSA were more often generated after than before the 
diagnosis of NAS.
Antibody- mediated rejection (AMR) as a result of DSA is a seri-
ous event in kidney, lung, and heart transplant recipients, associated 
with an increased risk of graft loss.1,2,26 Conversely, liver allografts 
were presumed to be highly resistant to DSA, mainly due to the liv-
er’s ability to absorb circulating anti- HLA antibodies. Indeed, in the 
current study, preformed DSA usually disappeared within a year after 
OLT—with class II persisting longer than class I. This property was even 
presumed to be one of the factors providing a protective effect against 
Univariate analysis Multivariate analysis
HR (95% CI) P- value HR (95% CI) P- value
Donor age 1.00 (0.98 – 1.02) .936
Donor gender male 
CMV IgG donor positive
0.76 (0.41 – 1.42) 
1.45 (0.78 – 2.68)
.392 
.238
CMV IgG recipient 
positive
1.30 (0.62 – 2.74) .491
Recipient age 
Recipient gender male
0.99 (0.96 – 1.02) 
1.06 (0.58 – 1.94)
.505 
.858
Gender mismatch 
BMI donor
0.86 (0.46 – 1.61) 
1.01 (0.92 – 1.12)
.642 
.802
OLT indication groupeda
OLT indication PSC
         (0.28 – 2.08) 
1.02 (0.50 – 2.08)
.897 
.964
Roux- en- Y anastomosis 
MELD score recipient
1.77 (0.54 – 5.82) 
1.02 (0.91 – 1.13)
.345 
.784
Preformed DSA Type I 
(>5000)
Preformed DSA Type II 
(>5000)
0.96 (0.34– 2.70) 
 
0.52 (0.12 – 2.15)
.933 
 
.366
Preformed DSA Type I  
(>1000)
Preformed DSA Type II  
(>1000)
0.90 (0.35 – 2.30) 
 
1.31 (0.32 – 5.46)
.829 
 
.708
CIT 
RWIT
1.00 (0.99 – 1.00) 
1.02 (0.99 – 1.03)
.244 
.079 1.02 (0.99 – 1.03) .079
HR, hazard ratio; CI, confidence intervals; OLT, orthotopic liver transplantation; CMV, 
cytomegalovirus,DBD, donation after brain death; DCD, donation after circulatory death; BMI, body 
mass index; NAS, nonanastomotic biliary strictures; DSA, donor- specific antibodies against HLA (mean 
fluorescence intensity (MFI)>5000).
aViral, alcoholic, (PSC) primary sclerosing cholangitis, or other underlying liver disease.
TABLE  4 Univariate and multivariate 
analyses of risk factors for NAS (DCD 
excluded)
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acute renal allograft rejection in simultaneous liver- kidney transplan-
tations and may be the result of release of soluble MHC complexes 
from the liver.27 However, a recent study demonstrated that renal al-
lograft protection by the liver is incomplete in case of preformed class 
II DSA and that, subsequently, despite some protection both grafts 
remain at risk for rejection.28 In addition, preformed and de novo DSA 
are increasingly recognized as a cause of rejection and allograft loss 
after OLT.7,8 This is probably the result of the ability of DSA to bind to 
endothelial cells in the portal triads leading to complement activation. 
Consistent with previous literature,8,29 DSA formed after OLT were, in 
the majority of cases, directed against class II antigens, mainly against 
HLA- DQ. Serial measurements demonstrated that antibodies against 
class II antigens tended to appear later after transplantation and to 
remain longer in the circulation compared to antibodies against class 
I antigens. Class II DSA have previously been associated with graft 
loss.30 The present study shows that after OLT, this is only the case for 
de novo class II DSA. The prevalence of preformed and de novo DSA in 
this study cohort was 9.9% and 21.2%, respectively. This is consistent 
with previous studies in which preformed DSA were detected in 5%- 
22% of the liver transplantation candidates.7,31,32 For de novo DSA, 
the reported prevalence varies between 8% and 24%.8,29,33
Bile duct complications after OLT are frequent and a major 
cause of morbidity and mortality. The role of DSA in the occur-
rence of bile duct complications after transplantation was unclear. 
Under physiological conditions, biliary epithelial cells highly express 
HLA class I antigens, whereas there is only a weak expression of 
class II  antigens.34 However, as a result of ischemia during OLT, a 
sterile  immune response is initiated, with elevated levels of pro- 
inflammatory cytokines (eg, interferon- γ and interleukins) and infil-
tration of inflammatory cells into the biliary epithelium, which can 
result in an upregulation of HLA class II antigens.21,35,36 Ischemia- 
reperfusion injury (IRI) of the biliary epithelium is also considered as 
one of the most important risk factors for NAS development. The 
effect of IRI is not limited to cholangiocytes only. In a previous study, 
we showed that severe IRI to hepatocytes, as reflected by a high 
peak alanine aminotransferase, was also an important risk factor for 
NAS  development.10 Interestingly, Gugenheim et al demonstrated an 
 upregulation of  hepatic class I antigen expression after a period of 
normothermic ischemia in a rat model.37
It could therefore be expected that a relation exists between IRI, 
the presence of antibodies against donor HLA antigens expressed 
on hepatocytes and biliary epithelium and bile duct complications, 
F IGURE  1 Donor- specific alloantibodies (DSA) status during follow- up in patients with nonanastomotic biliary strictures (NAS). Each patient 
is represented by a bar. The presence of class I and class II DSA is represented by different shades of gray. Repeated measurements were only 
available in a subgroup of NAS patients (n = 20)
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such as the development of nonanastomotic biliary strictures. In the 
present study, we could not find an association between preformed 
or de novo generated DSA and NAS. According to the present data, 
de novo DSA were also not related to NAS. De novo DSA—most of 
class II—generally developed after the diagnosis of NAS, supporting 
the conclusion that de novo DSA may worsen NAS, but probably are 
not involved in the initiation of NAS. This is in accordance with a study 
performed by Iacob et al.38 In that study, post- transplant DSA in re-
lation to both anastomotic and nonanastomotic biliary strictures was 
evaluated. The presence of post- transplant HLA class II DSA was re-
lated to the development of anastomotic strictures, but no association 
was found between the presence of alloantibodies and the occurrence 
of NAS. Yet, because of the cross- sectional design of that study, it re-
mained unclear whether these DSA were persistent or formed after 
transplantation, and several studies—including the current one—have 
demonstrated that predominantly de novo DSA are relevant in pre-
dicting transplantation outcome.8,9 Furthermore, the levels of DSA 
were not described by Iacob et al. In the present study, only DSA 
with an MFI of >5000 were considered positive, as mainly high MFI 
DSA are related to an inferior clinical outcome after OLT.7,9 Sensitivity 
analysis was performed in the current study for MFI>1000 with sim-
ilar outcomes. Other studies regarding this topic were not specific to 
NAS. For example, Takeya et al found an association between DSA 
and heterogeneous group of bile ducts complications, consisting of 
patients with biliary obstructions, biliary strictures and focal necrosis 
of the bile ducts.23 DSA have also been suggested to be related to 
ductopenia,39 which is most likely the result of chronic and irreversible 
rejection.22,40,41
A limitation of the present study is that from the majority of pa-
tients post- transplant DSA could only be measured 1 year after 
transplantation. Therefore, the influence of de novo DSA that are tran-
siently present, but are cleared from the circulation in the first year 
after transplantation, may have been missed in our analysis. This might 
have resulted in underestimation of the contribution of transient de 
novo class I DSA, which in a subgroup of patients that we analyzed 
longitudinally developed early after OLT but were cleared from the 
circulation within the first year after transplantation. Therefore, a pro-
spective study with repeated DSA measurements during follow- up is 
required to provide information on a possible association between 
transiently appearing de novo DSA and NAS development.
Another problem is that radiodiagnostic features of NAS resemble 
the diagnostic criteria for PSC. Therefore, it may be difficult to distin-
guish NAS and recurrence of PSC after OLT. As graft failure occurred 
in only four PSC patients (two without DSA and two with de novo 
class II DSA), and as PSC was not a risk factor for NAS in this study, we 
consider it unlikely that this has influenced our results.
According to the original Banff guidelines, the diagnosis of 
antibody- mediated rejection after kidney transplantation requires 
three criteria: morphologic evidence of tissue injury, serologic evi-
dence of DSA formation or other anti- donor endothelial antigens, and 
evidence of antibody interaction with vascular endothelium, for exam-
ple, C4d deposition in the peritubular capillaries.42 Recently, the crite-
ria were revised, and acute and chronic antibody- mediated rejection 
may now be diagnosed in the absence of C4d deposition. However, in 
this case, additional evidence of current or recent antibody interaction 
with the vascular endothelium must be present.43
Variables
Univariate analysis Multivariate analysis
HR (95% CI) P- value HR (95% CI) P- value
Recipient age 
at OLT
Continuous 1.02 (0.99 – 1.05) .254
Recipient 
gender
Male 2.47 (1.01 – 6.06) .049 2.69 (1.07 – 6.79) .036
Recipient BMI Continuous 1.04 (0.96 – 1.13) .320
Donation DCD 1.35 (0.55 – 3.35) .515
Donor age Continuous 1.02 (0.99 – 1.04) .259
Donor gender Male 1.35 (0.65 – 2.78) .420
Donor BMI Continuous 1.11 (0.99 – 1.25) .063 1.09 (0.96 – 1.24) .175
CMV mismatch Yes	(D+/R−) 0.65 (0.29 – 1.45) .288
Rejection Yes 0.80 (0.30 – 2.10) .650
Pre- OLT DSA Class I 1.69 (0.22 – 12.92) .612
Pre- OLT DSA Class II 0.73 (0.10 – 5.51) .760
NAS Time- 
dependent
8.05 (3.28 - 19.77) <.010
De novo DSA 
class II
Time- 
dependent
2.84 (1.38 – 5.82) <.010
HR, hazard ratio; CI, confidence intervals; OLT, orthotopic liver transplantation; CMV, cytomegalovirus, 
DBD, donation after brain death; DCD, donation after circulatory death; BMI, body mass index; NAS, 
nonanastomotic biliary strictures. Significant values are printed bold.
TABLE  5 Univariate and multivariate 
analyses of pre- OLT risk factors for graft 
loss
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In conclusion, the present study is the first study that assessed 
the relationship of DSA with nonanastomotic biliary stricture develop-
ment and graft survival after orthotopic liver transplantation. Neither 
preformed DSA nor de novo DSA generated within the first year after 
liver transplantation were associated with the development of NAS. 
However, the time- dependent analysis revealed that both NAS and 
de novo class II DSA developing after liver transplantation were inde-
pendently associated with graft loss.
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